Tags

Type your tag names separated by a space and hit enter

First trimester serum levels of the soluble transcobalamin receptor, holo-transcobalamin, and total transcobalamin in relation to preeclampsia risk.
Scand J Clin Lab Invest. 2016 Dec; 76(8):641-644.SJ

Abstract

BACKGROUND

Human placenta expresses CD320, a receptor that ensures the uptake of holo-transcobalamin (holoTC). Soluble CD320 (sCD320) is present in the circulation and its concentration increases during pregnancy.

AIMS

To investigate a possible association of sCD320, holoTC and total transcobalamin (TC) with the risk of subsequent preeclampsia using serum samples from asymptomatic first trimester pregnant women. Moreover, we aimed to establish reference intervals of the aforementioned biomarkers for first trimester pregnant women who remained healthy throughout pregnancy.

STUDY DESIGN

This study was a retrospective case-control study that we performed on biobank serum samples. Cases (n = 50) and controls (n = 198) (matched for gestational age and date of sample collection) were asymptomatic women in early pregnancy [median (range) gestational age = 10 (8-12) weeks]. Cases developed preeclampsia while the controls remained normotensive throughout pregnancy. We measured the serum concentration of sCD320, holoTC, and total TC by using in-house ELISA methods.

RESULTS

First trimester median concentrations of sCD320, holoTC and total TC were not significantly different between cases and controls. The odd ratio for developing preeclampsia based on exposure to low or high levels of sCD320, holoTC or total TC at first trimester was not significant. The reference intervals (2.5-97.5% percentiles (median)) derived from the controls were 50-170 (90) pmol\L for sCD320, 20-140 (70) pmol\L for holoTC and 560-1300 (810) pmol\L for total TC.

CONCLUSIONS

The risk of preeclampsia is not predicted by first trimester serum concentrations of sCD320, holoTC or total TC. The first trimester reference intervals for the three parameters is reported.

Authors+Show Affiliations

a Department of Clinical Biochemistry , Aarhus University Hospital , Aarhus , Denmark.a Department of Clinical Biochemistry , Aarhus University Hospital , Aarhus , Denmark.b Aarhus Institute for Advanced Studies, Aarhus University , Aarhus , Denmark.a Department of Clinical Biochemistry , Aarhus University Hospital , Aarhus , Denmark.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27700208

Citation

Abuyaman, Omar, et al. "First Trimester Serum Levels of the Soluble Transcobalamin Receptor, Holo-transcobalamin, and Total Transcobalamin in Relation to Preeclampsia Risk." Scandinavian Journal of Clinical and Laboratory Investigation, vol. 76, no. 8, 2016, pp. 641-644.
Abuyaman O, Torring N, Obeid R, et al. First trimester serum levels of the soluble transcobalamin receptor, holo-transcobalamin, and total transcobalamin in relation to preeclampsia risk. Scand J Clin Lab Invest. 2016;76(8):641-644.
Abuyaman, O., Torring, N., Obeid, R., & Nexo, E. (2016). First trimester serum levels of the soluble transcobalamin receptor, holo-transcobalamin, and total transcobalamin in relation to preeclampsia risk. Scandinavian Journal of Clinical and Laboratory Investigation, 76(8), 641-644.
Abuyaman O, et al. First Trimester Serum Levels of the Soluble Transcobalamin Receptor, Holo-transcobalamin, and Total Transcobalamin in Relation to Preeclampsia Risk. Scand J Clin Lab Invest. 2016;76(8):641-644. PubMed PMID: 27700208.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - First trimester serum levels of the soluble transcobalamin receptor, holo-transcobalamin, and total transcobalamin in relation to preeclampsia risk. AU - Abuyaman,Omar, AU - Torring,Niels, AU - Obeid,Rima, AU - Nexo,Ebba, Y1 - 2016/10/04/ PY - 2016/10/5/pubmed PY - 2017/3/24/medline PY - 2016/10/5/entrez KW - Cobalamin KW - Vitamin B12 KW - preeclampsia risk KW - pregnancy KW - sCD320 KW - transcobalamin SP - 641 EP - 644 JF - Scandinavian journal of clinical and laboratory investigation JO - Scand J Clin Lab Invest VL - 76 IS - 8 N2 - BACKGROUND: Human placenta expresses CD320, a receptor that ensures the uptake of holo-transcobalamin (holoTC). Soluble CD320 (sCD320) is present in the circulation and its concentration increases during pregnancy. AIMS: To investigate a possible association of sCD320, holoTC and total transcobalamin (TC) with the risk of subsequent preeclampsia using serum samples from asymptomatic first trimester pregnant women. Moreover, we aimed to establish reference intervals of the aforementioned biomarkers for first trimester pregnant women who remained healthy throughout pregnancy. STUDY DESIGN: This study was a retrospective case-control study that we performed on biobank serum samples. Cases (n = 50) and controls (n = 198) (matched for gestational age and date of sample collection) were asymptomatic women in early pregnancy [median (range) gestational age = 10 (8-12) weeks]. Cases developed preeclampsia while the controls remained normotensive throughout pregnancy. We measured the serum concentration of sCD320, holoTC, and total TC by using in-house ELISA methods. RESULTS: First trimester median concentrations of sCD320, holoTC and total TC were not significantly different between cases and controls. The odd ratio for developing preeclampsia based on exposure to low or high levels of sCD320, holoTC or total TC at first trimester was not significant. The reference intervals (2.5-97.5% percentiles (median)) derived from the controls were 50-170 (90) pmol\L for sCD320, 20-140 (70) pmol\L for holoTC and 560-1300 (810) pmol\L for total TC. CONCLUSIONS: The risk of preeclampsia is not predicted by first trimester serum concentrations of sCD320, holoTC or total TC. The first trimester reference intervals for the three parameters is reported. SN - 1502-7686 UR - https://www.unboundmedicine.com/medline/citation/27700208/First_trimester_serum_levels_of_the_soluble_transcobalamin_receptor_holo_transcobalamin_and_total_transcobalamin_in_relation_to_preeclampsia_risk_ L2 - https://www.tandfonline.com/doi/full/10.1080/00365513.2016.1230885 DB - PRIME DP - Unbound Medicine ER -